Safeguarding public health has long been HKUMed’s core mission, from the 1894 Taipingshan plague to COVID-19. Our health care professionals and scientists have been at the forefront in the battle against COVID-19 since the very beginning of the pandemic. Now, we are supporting the most important phase of pandemic control by operating one of the designated community vaccination centres.

In so doing, we will also be carrying out lifesaving research into further ensuring the safety and effectiveness of vaccines, to give added protection for those who choose to enrol in our research programmes and more broadly to advance the science of vaccinology against COVID-19. 

Starting 16 March, we will be responsible for the Community Vaccination Centre at Ap Lei Chau Sports Centre (ALC CVC, #8 in the government directory), where we will administer the COVID-19 mRNA Vaccine: Comirnaty (BNT 162b2) from Fosun Pharma/BioNTech.

At the same time, we will be recruiting volunteers for vaccination research studies that will produce new knowledge for the next stage of COVID-19 control.

由1894年太平山鼠疫,到今天新冠肺炎大流行,港大醫學院一直致力守護香港人健康。我們的醫護及研究人員,早於疫情之初,已在抗疫戰前線奮鬥。現在來到控制疫情的最重要階段,港大醫學院將營運其中一間社區疫苗接種中心,替廣大市民接種疫苗。

我們亦將展開研究,進一步確保疫苗安全和效用;為參與研究計劃的人士提供額外保障,並推動醫學界發掘和了解新冠肺炎疫苗更多。 

由3月16日起,我們將負責營運鴨脷洲體育館社區疫苗接種中心(中心名單#8),提供由復星醫藥與德國藥廠BioNTech共同研發的信使核糖核酸新冠疫苗「復必泰」(BNT 162b2)。 

與此同時,我們正為疫苗研究招募參加者,為制定下一階段的抗疫措施提供新見解。